$PLRX from a fundamental standpoint Pliant Therapeutics looks ridiculously cheap right now.
The stock is trading at $1.21, giving it a market cap of roughly $74M
Total cash and equivalents: $241.8 million. This results in a net cash position of about $182 million (after subtracting ~$60 million in debt), or roughly $3 per share in net cash alone.
The entire company is valued at only about 30β34% of its cash on hand.
Stock is trading at a massive discount to its cash reserves.
ππ These guys are here to win big
$PLRX from a fundamental standpoint Pliant Therapeutics looks ridiculously cheap right now.
The stock is trading at $1.21, giving it a market cap of roughly $74M
Total cash and equivalents: $241.8 million. This results in a net cash position of about $182 million (after subtracting ~$60 million in debt), or roughly $3 per share in net cash alone.
The entire company is valued at only about 30β34% of its cash on hand.
Stock is trading at a massive discount to its cash reserves.
ππ These guys are here to win big
$ASST .73 Strive, Inc. (Nasdaq: ASST) announced a 1-for-20 reverse stock split of its Class A and Class B common stock, approved by shareholders in January 2026 in conjunction with its acquisition of Semler Scientific.
Sending $2,700 of todayβs $PBR swing profits to someone who likes this tweet πΊπΈ
Turn my notifications on π
(Must be following to DM) $SPY $SPX
$BEEM $AMD $ALTS